Market Overview

Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal

Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal
Related TSRO
Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
5 Biotech Companies To Keep On Your M&A Watchlist For 2019
What One Sector Offers Safety As Markets Get Roiled? (Seeking Alpha)
Related GSK
Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
Jim Cramer Gives His Opinion On GlaxoSmithKline, Abbott Laboratories And More
Glaxosmithkline Earns Relative Strength Rating Upgrade (Investor's Business Daily)

GlaxoSmithKline plc (NYSE: GSK) on Monday announceda $5.1 billion deal to acquire Tesaro Inc (NASDAQ: TSRO) in a bid to augment its oncology franchise.

The Analyst

Wedbush analyst David Nierengarten downgraded Tesaro from Outperform to Neutral and upped the price target from $60 to $75.

The Thesis

Glaxo is likely to benefit from Tesaro's mature oncology program and acquired talent in the oncology space, Nierengarten wrote in a Tuesday note.

The analyst noted worldwide sales of Tesaro's lead asset Zejula was $63.2 million in Q3, ahead of his $58.2 million estimate, with the 17 percent sequential growth attributable to strong sales in Germany and the UK, and expanding sales in Italy and Switzerland.

With roughly 25 percent of Zejula net sales coming from the EU, Nierengarten expects Glaxo to step up efforts to market it vigorously in Europe as well as the United States.

Glaxo would gain access to Tesaro's clinical programs as well as multiple assets from a license agreement with AnaptysBio Inc (NASDAQ: ANAB).

"We view TESARO's valuation as attractive on a risk/reward basis with approved products Zejula and Varubi, and see TSRO's immuno-oncology platform driving significant value going forward," the analyst wrote.

The firm sees the Q4 sNDA submission for Zejula in late-line ovarian cancer as the next upcoming catalyst.

Price Action

Following a 59 percent jump on Monday, Tesaro shares traded around $73.96 Tuesday afternoon.

Related Links:

Global Blood's Sickle Cell Disease Drug Snags Accelerated FDA Approval Pathway

The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Latest Ratings for TSRO

Dec 2018BarclaysDowngradesOverweightEqual-Weight
Dec 2018WedbushDowngradesOutperformNeutral
Dec 2018Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for TSRO
View the Latest Analyst Ratings

Posted-In: David Nierengarten WedbushAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (GSK + ANAB)

View Comments and Join the Discussion!

Latest Ratings

MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

FreightWaves Releases Commercial Vehicle Accident Data In SONAR

Utah Legislature Passes Compromise Medical Marijuana Bill